Cure8 news brief
Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term results in Crohn’s disease.
If durable across patient groups, IL-23 p19 inhibition could be an important option for people who have failed other therapies.
Adults with moderately to severely active Crohn’s disease, patients considering or currently on biologic therapy, gastroenterology clinicians, and researchers studying IL-23 pathway treatments.
A University of Cincinnati physician-scientist led publication of five-year efficacy and safety results from the GALAXI 1 long-term extension study of guselkumab (Tremfya) for moderately to severely active Crohn’s disease.
The report, published in Inflammatory Bowel Diseases, presents sustained clinical remission and objective endoscopic responses among patients who remained on therapy for five years, and notes no new safety signals.
The article summarizes the trial program led by the investigator, linking earlier induction and maintenance publications and later phase 3 confirmations. It highlights that benefits were seen regardless of prior biologic exposure and emphasizes IL-23 p19 inhibition as a durable, mechanism-based treatment approach.
The study was funded by Johnson & Johnson and represents long-term follow-up rather than a new randomized trial. What this doesn’t do: The university news piece reports on published trial data but does not provide full study tables, patient-level details, or regulatory implications.
It is a summary aimed at highlighting the investigator’s role and the significance of long-term follow-up.
This is a university news summary of a five-year long-term extension analysis published in a peer-reviewed journal. It reports outcomes for patients who remained on therapy (not an intention-to-treat snapshot), and was funded by the drug manufacturer.
The original Inflammatory Bowel Diseases article should be consulted for detailed methods, endpoints, and limitations before drawing conclusions about individual treatment decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
